Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Ventrus Contracts inVentiv, Almac for Phase III Trial | Contract Pharma

What are you searching for?

Sign in
Breaking News

Ventrus Contracts inVentiv, Almac for Phase III Trial

Ventrus Biosciences has selected inVentiv Clinical Solutions to manage its Phase III trial with Iferanserin in development for the treatment of hemorrhoids.

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Ventrus Biosciences has selected inVentiv Clinical Solutions to manage its Phase III trial with Iferanserin in development for the treatment of hemorrhoids. Ventrus has selected Almac Group to provide electronic patient-reported outcomes solutions.

Ventrus plans to initiate its first Phase III trial in 2011 and expects data in 1Q12. The study will enroll 400 patients who will be randomized to receive placebo or Iferanserin. The primary endpoint is cessation of bleeding.

Russell Ellison, chief executive officer of Ventrus, said, “During our selection process, we were looking for strategic partners who have a proven track record with gastrointestinal studies and track record of success. inVentiv and Almac rose above the other research organizations and we are delighted to be working with them.”


Click here to learn more about Almac Group

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters